H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating, Maintains Target Price $7
Cautious Hold Rating on Agenus Amid Strategic Realignment and Financial Challenges
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Agenus (AGEN) and SAGE Therapeutics (SAGE)
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $11
B. Riley Adjusts Agenus Price Target to $11 From $18, Maintains Buy Rating
Promising Developments and Strategic Financing Enhance Agenus's Buy Rating Amidst Stock Volatility
Agenus Is Maintained at Neutral by HC Wainwright & Co.
Agenus Analyst Ratings
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating, Cuts Target Price to $7
Agenus Analyst Ratings
B. Riley Adjusts Price Target on Agenus to $18 From $42, Maintains Buy Rating
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $18
Agenus Hold Rating: Balancing Phase 2 Progress With Regulatory Challenges and Uncertainty
Jefferies Downgrades Agenus to Hold, Raises Price Target to $7
Agenus Downgraded at Baird After FDA Feedback on Cancer Drug
HC Wainwright Downgrades Agenus to Neutral From Buy, Adjusts Price Target to $9 From $40
Hold Rating Justified for Agenus Amidst Regulatory Uncertainties and Mixed Clinical Results
HC Wainwright & Co. Downgrades Agenus to Neutral, Lowers Price Target to $9
Agenus Analyst Ratings
Agenus Analyst Ratings